Form 4: Rocket Pharmaceuticals Executive Sells Shares

Mark Andrew White, a General Manager at Rocket Pharmaceuticals, sold 3,026 shares of common stock at a price of $20.395 on July 8, 2024.

Summary

• On July 8, 2024, Mark Andrew White, a General Manager at Rocket Pharmaceuticals, sold 3,026 shares of common stock.
• The sale price was $20.395 per share.
• Following the transaction, White directly owns 72,220 shares of Rocket Pharmaceuticals.
• The holdings include Restricted Stock Units (RSUs) that convert to common stock on a one-for-one basis.
• RSUs vest one-third (1/3) upon the first anniversary of the grant date, with the remaining shares vesting in equal quarterly installments over the following two years.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a routine disclosure of an insider stock sale. The sale itself doesn't necessarily indicate a positive or negative outlook.

Industry Context

This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company executives.

Stakeholder Impact

• The sale of shares by a company insider could be perceived negatively by some shareholders, although it is a relatively small transaction.

Key Dates